[Pharmacological justification for the use of new antidepressant drugs].
This review compares a new generation of antidepressants with standard tricyclic antidepressants. It is now believed that an ideal antidepressant should be characterised by high therapeutic efficacy, good tolerance, safety of use related to low incidence of adverse effects, little potential for interactions and low cost of use. Mirtazapine, nefazodone and venlafaxine have therapeutic efficacy which is comparable with that of tricyclic antidepressants and their lack of (or insignificant) receptor effect as well as double mechanism of action makes them a safer therapeutic option.
Nowakowska
Elzbieta
E
Zakład Farmakologii Akademii Medycznej im. K. Marcinkowskiego w Poznaniu.
Kus
Krzysztof
K
Bobkiewicz-Kozłowska
Teresa
T
D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology* / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology / Q000627:therapeutic use; D003511:Cyclohexanols / Q000494:pharmacology / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D008803:Mianserin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000078785:Mirtazapine; D010879:Piperazines; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D010879:Piperazines; D014230:Triazoles; D008803:Mianserin; C051752:nefazodone; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine